COSTOYaNIE SISTEMY OSTEOPROTEGERIN (OPG) - LIGAND RETsEPTORA-AKTIVATORA YaDERNOGO FAKTORA KAPPA-V (RANKL)u patsientov s diabeticheskoy osteoartropatiey i mediakal'tsinozom arteriy nizhnikh konechnostey

Abstract


That were 107 patients included. 33 patients with acute stage of diabetic osteoarthropathy, 24 patients with chronic stage; 20 patients with severe diabetic neuropathy and medial arterial calcification (MAC) of the low extremity, confirmed X-rays; control group included 30 persons with normal glucose tolerance. Significant increased level of OPG revealed in all groups of patients with diabetes (р<0,0001). The highest values OPG were marked in patients with MAC (р<0,02). Positive correlations revealed between bone-specific alkaline phosphatase (BAP) values and OPG (r=0,2 р<0,01) and BAP and RANKL (r=0,21 р<0,01) in groups of patients with diabetic osteoarthropathy. Negative correlation revealed between OPG and RANKL in patients with MAC (r=-0,68 р<0,001) and negative correlation revealed between values of mineral bone density and OPG in patients with MAC (r=-0,61 p<0,002).

About the authors

M. V. YaROSLAVTsEVA

I. N. UL'YaNOVA

G R GALSTYaN

A. V. IL'IN

L. V. NIKANKINA

O. V. REMIZOV

References

  1. Беневоленская Л. И. / Руководство по остеопорозу. // - М.: БИНОМ. Лаборатория знаний, 2003. - с.82
  2. Шварц Г. Я. / Молекулярно-биологические основы создания новых лекарственных средств для лечения остеопороза: 1. Остеопротегерин, ЛОПГ (RANKL) и RANK: физиологический механизм (ы) регуляции костной резорбции. Обзор литературы. // Остеопороз и остеопатии № 2, 2003. - с.21-22
  3. Abedin M., Tintut Y., Demer L. / Vascular calcification: mechanisms and clinical ramifications. // Aterosclerosis, thrombosis, and vascular biology, 2004; 24; 1164-1170.
  4. Browner W. S., Lui L. Y., Cummings S. R. / Associations of serum osteoprotegerin levels wits diabetes, stroke, bone density, fractures, and mortality in elderly women. // J Clin Endocrinol Metab 2001; 86: 631-37.
  5. Hofbauer L., Shoppet M. / Osteoprotegerin: a link between osteoporosis and arterial calcification? // The Lancet. Vol.358, July 28, 2001.
  6. Hofbauer L. C., Shui C., Riggs B. L., et al. / Effects of immunosuppressants on receptor activator of NF-kB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cell. // Biochem Biophys Res Commun 2001; 280:334-39.
  7. Jeffcoate W. / Vascular calcification and osteolysis in diabetic neuropathy - is RANK-L the missing link? // Diabetologia 2004. 47:1488-1492.
  8. Malyankar U. M., Scatena M., Suchland K. L., Yun T. J., Clarc E. A., Giachechelli C. M. / Osteopronegerin is an aß-induced, NF-kB-dependent survival factor for endothelial cells. // J. Biol.Chem 2000; 275: 20959-62.
  9. Min H., Morony S., Sarosi I., et. al. / Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. // J. Exp Med 2000; 192: 463-74.
  10. Schoppet M., Sattler A.N.M., Schaefer J. R., Herzum M., Maisch B., Hofbauer L. C. / Increased osteoprotegerin serum levels in men with coronary artery disease. // J. Clin Endocrinol. Metabol. 2003, 88: 1024-1028.
  11. Simmonet W. S., Lacey D. L., Dunstan C. R., et al. / Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. // Cell 89: 309-319.
  12. Tsuda E., Goto M., Mochizuki S. et al. / Isolation of a novel cytokine from human fibroblasts that specifically inhibites the osteoclastogenesis // Biochem. Biophys. Res. Comm. 1997 V.234 P. 137-142
  13. Yasuda H., Shima N., Nakagawa N., et al. / Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. // 1998, Endocrinology 39:1329-1337.

Statistics

Views

Abstract - 676

Cited-By


PlumX

Dimensions


Copyright (c) 2008 YaROSLAVTsEVA M.V., UL'YaNOVA I.N., GALSTYaN G.R., IL'IN A.V., NIKANKINA L.V., REMIZOV O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies